Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 2 73,"Stieber D, et al., Int J Cancer. 2007 Jan 17",mammary gland integrity trait,,RS:0001449,SPRD/Ztm,female,191 days to 186 days,48,,CMO:0000343,mammary tumor number,,,,11.23,,0.0736,0.51,MMO:0000344,necropsy,,0,necropsy,DMBA oral gavage,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",11340,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",, 73,"Stieber D, et al., Int J Cancer. 2007 Jan 17",mammary gland integrity trait,,RS:0001450,SPRD.WKY-(D18Wox8-D18Rat44)/Ibmm,female,191 days to 186 days,46,,CMO:0000343,mammary tumor number,,,,7.61,,0.0663,0.45,MMO:0000344,necropsy,,0,necropsy,DMBA oral gavage,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",11342,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",, 73,"Stieber D, et al., Int J Cancer. 2007 Jan 17",mammary gland integrity trait,,RS:0001452,SPRD.WKY-(D5Rat190-D5Rat114)/Ibmm,female,191 days to 186 days,14,,CMO:0000343,mammary tumor number,,,,3.93,,0.171,0.64,MMO:0000344,necropsy,,0,necropsy,DMBA oral gavage,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",11341,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",, 74,"Piessevaux G, et al., Mamm Genome. 2008 Dec 4",mammary gland integrity trait,,RS:0002196,SPRD.WKY-(D10Rat91-D10Rat135)/Ibmm,female,0 days,25,,CMO:0000343,mammary tumor number,,,,9.24,,0.65,3.25,MMO:0000158,manual palpation method,,0,,DMBA oral gavage,133,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 133 days)",11357,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 133 days)",, 74,"Piessevaux G, et al., Mamm Genome. 2008 Dec 4",mammary gland integrity trait,,RS:0001450,SPRD.WKY-(D18Wox8-D18Rat44)/Ibmm,female,0 days,46,,CMO:0000343,mammary tumor number,,,,7.61,,0.45,3.052,MMO:0000158,manual palpation method,,0,,DMBA oral gavage,133,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 133 days)",11356,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 133 days)",, 74,"Piessevaux G, et al., Mamm Genome. 2008 Dec 4",mammary gland integrity trait,,RS:0001452,SPRD.WKY-(D5Rat190-D5Rat114)/Ibmm,female,0 days,14,,CMO:0000343,mammary tumor number,,,,3.93,,0.64,2.3947,MMO:0000158,manual palpation method,,0,,DMBA oral gavage,133,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 133 days)",11355,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 133 days)",, 74,"Piessevaux G, et al., Mamm Genome. 2008 Dec 4",mammary gland integrity trait,,RS:0001449,SPRD/Ztm,female,0 days,17,,CMO:0000343,mammary tumor number,,,,10.89,,0.43,1.7729,MMO:0000158,manual palpation method,,0,,DMBA oral gavage,133,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 133 days)",11354,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 133 days)",, 74,"Piessevaux G, et al., Mamm Genome. 2008 Dec 4",mammary gland integrity trait,,RS:0002197,SPRD.WKY-(D5Rat190-D5Rat114)(D18Rat102-D18Rat44)/Ibmm,female,0 days,33,,CMO:0000343,mammary tumor number,,,,5,,0.44,2.5276,MMO:0000158,manual palpation method,,0,,DMBA oral gavage,133,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 133 days)",11358,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 133 days)",, 75,"Kurz SG, et al., Endocrinology. 2008 Apr 17",mammary gland integrity trait,,RS:0000185,COP/CrCrl,female,259 days,7,,CMO:0000343,mammary tumor number,,,,0.1,,0.1512,0.4,MMO:0000344,necropsy,,,,,,,17 beta-estradiol (27.5 mg) (for 196 days),11370,17 beta-estradiol (27.5 mg) (for 196 days),, 75,"Kurz SG, et al., Endocrinology. 2008 Apr 17",mammary gland integrity trait,,RS:0000185,COP/CrCrl,female,259 days,5,,CMO:0000343,mammary tumor number,,,,0,,,,MMO:0000344,necropsy,,,,,,,control condition,11369,control condition,, 75,"Kurz SG, et al., Endocrinology. 2008 Apr 17",mammary gland integrity trait,,RS:0000032,ACI/SegHsd,female,259 days,21,,CMO:0000343,mammary tumor number,,,,7,,1.1566,5.3,MMO:0000344,necropsy,,,,,,,17 beta-estradiol (27.5 mg) (for 196 days),11368,17 beta-estradiol (27.5 mg) (for 196 days),, 75,"Kurz SG, et al., Endocrinology. 2008 Apr 17",mammary gland integrity trait,,RS:0000032,ACI/SegHsd,female,259 days,4,,CMO:0000343,mammary tumor number,,,,0,,,,MMO:0000344,necropsy,,,,,,,control condition,11367,control condition,, 75,"Kurz SG, et al., Endocrinology. 2008 Apr 17",mammary gland integrity trait,,RS:0001158,ACI.COP-(D10Mgh8-D10Rat4)/Shul,female,259 days,12,,CMO:0000343,mammary tumor number,,,,4.8,,1.0392,3.6,MMO:0000344,necropsy,,,,,,,17 beta-estradiol (27.5 mg) (for 196 days),11366,17 beta-estradiol (27.5 mg) (for 196 days),, 75,"Kurz SG, et al., Endocrinology. 2008 Apr 17",mammary gland integrity trait,,RS:0001158,ACI.COP-(D10Mgh8-D10Rat4)/Shul,female,259 days,3,,CMO:0000343,mammary tumor number,,,,0,,,,MMO:0000344,necropsy,,,,,,,control condition,11365,control condition,, 75,"Kurz SG, et al., Endocrinology. 2008 Apr 17",mammary gland integrity trait,,RS:0001160,ACI.COP-(D3Rat130-D3Rat114)/Shul,female,259 days,17,,CMO:0000343,mammary tumor number,,,,4.5,,0.7276,3.0,MMO:0000344,necropsy,,,,,,,17 beta-estradiol (27.5 mg) (for 196 days),11364,17 beta-estradiol (27.5 mg) (for 196 days),, 75,"Kurz SG, et al., Endocrinology. 2008 Apr 17",mammary gland integrity trait,,RS:0001160,ACI.COP-(D3Rat130-D3Rat114)/Shul,female,259 days,3,,CMO:0000343,mammary tumor number,,,,0,,,,MMO:0000344,necropsy,,,,,,,control condition,11363,control condition,, 75,"Kurz SG, et al., Endocrinology. 2008 Apr 17",mammary gland integrity trait,,RS:0001159,ACI.COP-(D3Mgh16-D3Rat119)/Shul,female,259 days,8,,CMO:0000343,mammary tumor number,,,,4.3,,1.1314,3.2,MMO:0000344,necropsy,,,,,,,17 beta-estradiol (27.5 mg) (for 196 days),11362,17 beta-estradiol (27.5 mg) (for 196 days),, 75,"Kurz SG, et al., Endocrinology. 2008 Apr 17",mammary gland integrity trait,,RS:0001159,ACI.COP-(D3Mgh16-D3Rat119)/Shul,female,259 days,3,,CMO:0000343,mammary tumor number,,,,0,,,,MMO:0000344,necropsy,,,,,,,control condition,11361,control condition,, 75,"Kurz SG, et al., Endocrinology. 2008 Apr 17",mammary gland integrity trait,,RS:0001161,ACI.COP-(D6Rat80-D6Rat146)/Shul,female,259 days,17,,CMO:0000343,mammary tumor number,,,,2.4,,0.4123,1.7,MMO:0000344,necropsy,,,,,,,17 beta-estradiol (27.5 mg) (for 196 days),11360,17 beta-estradiol (27.5 mg) (for 196 days),, 75,"Kurz SG, et al., Endocrinology. 2008 Apr 17",mammary gland integrity trait,,RS:0001161,ACI.COP-(D6Rat80-D6Rat146)/Shul,female,259 days,3,,CMO:0000343,mammary tumor number,,,,0,,,,MMO:0000344,necropsy,,,,,,,control condition,11359,control condition,, 76,"Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601",mammary gland integrity trait,,RS:0000032,ACI/SegHsd,female,260 days to 160 days,20,,CMO:0000343,mammary tumor number,,,,5.6,,,,MMO:0000344,necropsy,,0.0,tumor size reach 1-1.5 cm,,,,17 beta-estradiol (27.5 mg) (between 99 and 197 days),11377,17 beta-estradiol (27.5 mg) (between 99 and 197 days),, 86,"Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45",mammary gland integrity trait,,RS:0000800,SS-Chr 19BN/Mcwi,female,162 days to 152 days,14,,CMO:0000343,mammary tumor number,,,,8.79,,1.2508,4.68,MMO:0000344,necropsy,,0,necropsy,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",11507,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 86,"Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45",mammary gland integrity trait,,RS:0000797,SS-Chr 16BN/Mcwi,female,162 days to 152 days,13,,CMO:0000343,mammary tumor number,,,,6.31,,1.6059,5.79,MMO:0000344,necropsy,,0,necropsy,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",11504,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 86,"Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45",mammary gland integrity trait,,RS:0000794,SS-Chr 13BN/Mcwi,female,162 days to 152 days,13,,CMO:0000343,mammary tumor number,,,,5.33,,1.2148,4.38,MMO:0000344,necropsy,,0,necropsy,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",11501,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 86,"Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45",mammary gland integrity trait,,RS:0000811,SS/JrHsdMcwi,female,162 days to 152 days,40,,CMO:0000343,mammary tumor number,,,,2.45,,0.2087,1.32,MMO:0000344,necropsy,,0,necropsy,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",11488,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 86,"Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45",mammary gland integrity trait,,RS:0001486,SS.BN-(D13Hmgc64-RN34_13048990782)/Mcwi,female,162 days to 152 days,14,,CMO:0000343,mammary tumor number,,,,4.86,,0.7029,2.63,MMO:0000344,necropsy,,0,necropsy,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",65573,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 86,"Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45",mammary gland integrity trait,,RS:0002482,SS.BN-(D6Rat149-D6Arb3)/Mcwi,female,162 days to 152 days,14,,CMO:0000343,mammary tumor number,,,,4.77,,0.6388,2.39,MMO:0000344,necropsy,,0,necropsy,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",65571,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 81,"Schaffer BS, et al., Cancer Res. 2006 Aug 1;66(15):7793-800",mammary gland integrity trait,,RS:0000032,ACI/SegHsd,female,259 days to 143 days,22,,CMO:0000343,mammary tumor number,,,,8.8,,1.4,6.5666,MMO:0000158,manual palpation method,,0.0,,crystalline implant,,,17 beta-estradiol (27.5 mg) (between 193 and 199 days),11382,17 beta-estradiol (27.5 mg) (between 193 and 199 days),, 81,"Schaffer BS, et al., Cancer Res. 2006 Aug 1;66(15):7793-800",mammary gland integrity trait,,RS:0000155,BN/SsNHsd,female,259 days,13,,CMO:0000343,mammary tumor number,,,,0,,,,MMO:0000158,manual palpation method,,,,crystalline implant,,,17 beta-estradiol (27.5 mg) (between 196 and 199 days),11381,17 beta-estradiol (27.5 mg) (between 196 and 199 days),, 141,"Lan H, et al., Genetics 2001 Jan;157(1):331-9",mammary gland integrity trait,,RS:0000916,WKY/NHsd,female,174 days to 169 days,17,,CMO:0000343,mammary tumor number,,3X3 mm diameter or larger,,0,,,,MMO:0000344,necropsy,,,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",11741,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",, 141,"Lan H, et al., Genetics 2001 Jan;157(1):331-9",mammary gland integrity trait,,RS:0000984,WF/NHsd,female,174 days to 169 days,21,,CMO:0000343,mammary tumor number,,3X3 mm diameter or larger,,7.3,,0.982,4.5,MMO:0000344,necropsy,,,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",11742,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",, 142,"Samuelson DJ, et al., Carcinogenesis 2003 Sep;24(9):1455-60",mammary gland integrity trait,,RS:0000984,WF/NHsd,female,160 days to 155 days,50,,CMO:0000343,mammary tumor number,,3X3 mm diameter or larger,,6.9,,0.4,2.8284,MMO:0000160,unspecified method,,,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",11743,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",, 142,"Samuelson DJ, et al., Carcinogenesis 2003 Sep;24(9):1455-60",mammary gland integrity trait,,RS:0001000,WF.WKY-(D5Wox7-D5Uwm37)/Uwm,female,160 days to 155 days,13,,CMO:0000343,mammary tumor number,,3X3 mm diameter or larger,,1.1,,0.3,1.0817,MMO:0000160,unspecified method,,,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",11744,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",, 142,"Samuelson DJ, et al., Carcinogenesis 2003 Sep;24(9):1455-60",mammary gland integrity trait,,RS:0002541,WF.WKY-(D5Rat26-D5Uwm42)/Uwm,female,160 days to 155 days,29,,CMO:0000343,mammary tumor number,,3X3 mm diameter or larger,,5.7,,0.6,3.2311,MMO:0000160,unspecified method,,,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",11745,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",, 143,"Haag JD, et al., Cancer Res 2003 Sep 15;63(18):5808-12",mammary gland integrity trait,,RS:0000984,WF/NHsd,female,160 days to 155 days,30,,CMO:0000343,mammary tumor number,,3X3 mm diameter or larger,,8.1,,0.7,3.8341,MMO:0000344,necropsy,,,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",11746,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",, 143,"Haag JD, et al., Cancer Res 2003 Sep 15;63(18):5808-12",mammary gland integrity trait,,RS:0000186,COP/OlaHsd,female,160 days to 155 days,16,,CMO:0000343,mammary tumor number,,3X3 mm diameter or larger,,0.25,,0.1,0.4,MMO:0000344,necropsy,,,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",11747,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",, 143,"Haag JD, et al., Cancer Res 2003 Sep 15;63(18):5808-12",mammary gland integrity trait,,RS:0000984,WF/NHsd,female,160 days to 155 days,29,,CMO:0000343,mammary tumor number,,3X3 mm diameter or larger,,6.3,,0.5,2.6926,MMO:0000344,necropsy,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",70167,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",, 143,"Haag JD, et al., Cancer Res 2003 Sep 15;63(18):5808-12",mammary gland integrity trait,,RS:0000994,WF.COP-(D2Mit29-D2Rat201)/Uwm,female,160 days to 155 days,19,,CMO:0000343,mammary tumor number,,3X3 mm diameter or larger,,1.5,,0.3,1.3077,MMO:0000344,necropsy,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",70168,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) ",, 144,"Shull JD, et al., Endocrinology 2001 Dec;142(12):5124-30",mammary gland integrity trait,,RS:0000186,COP/OlaHsd,female,397 days to 271 days,20,,CMO:0000343,mammary tumor number,,,,0.4,,0.1342,0.6,MMO:0000158,manual palpation method,,0,,,,,17 beta-estradiol (27.5 mg) (between 212 and 330 days),11753,17 beta-estradiol (27.5 mg) (between 212 and 330 days),, 144,"Shull JD, et al., Endocrinology 2001 Dec;142(12):5124-30",mammary gland integrity trait,,RS:0000032,ACI/SegHsd,female,264 days to 203 days,34,,CMO:0000343,mammary tumor number,,,,3.9,,0.6002,3.5,MMO:0000158,manual palpation method,,0,,,,,17 beta-estradiol (27.5 mg) (between 144 and 195 days),11752,17 beta-estradiol (27.5 mg) (between 144 and 195 days),, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003347,WF.WKY-(D5Uwm67-D5Uwm98)/Uwm,female,160 days to 155 days,35,,CMO:0000343,mammary tumor number,,,,3.2,,0.4,2.3664,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70296,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003348,WF.WKY-(D5Uwm76-D5Uwm61)/Uwm,female,160 days to 155 days,40,,CMO:0000343,mammary tumor number,,,,4.2,,0.4,2.5298,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70297,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003349,WF.WKY-(D5Uwm76-D5Uwm98)/Uwm,female,160 days to 155 days,26,,CMO:0000343,mammary tumor number,,,,3.8,,0.4,2.0396,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70298,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003350,WF.WKY-(D5Uwm67-D5Uwm78)/Uwm,female,160 days to 155 days,32,,CMO:0000343,mammary tumor number,,,,8.6,,0.8,4.5255,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70299,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003351,WF.WKY-(D5Uwm76-D5Got18)/Uwm,female,160 days to 155 days,27,,CMO:0000343,mammary tumor number,,,,3.5,,0.4,2.0785,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70300,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003352,WF.WKY-(D5Uwm78-D5Uwm98)/Uwm,female,160 days to 155 days,32,,CMO:0000343,mammary tumor number,,,,2.8,,0.3,1.6971,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70301,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003353,WF.WKY-(D5Uwm95-D5Uwm98)/Uwm,female,160 days to 155 days,36,,CMO:0000343,mammary tumor number,,,,7.4,,0.6,3.6,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70302,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003354,WF.WKY-(D5Uwm67-D5Uwm81)/Uwm,female,160 days to 155 days,26,,CMO:0000343,mammary tumor number,,,,8.3,,0.7,3.5693,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70303,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003355,WF.WKY-(D5Uwm76-D5Uwm92)/Uwm,female,160 days to 155 days,58,,CMO:0000343,mammary tumor number,,,,4.8,,0.4,3.0463,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70304,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003356,WF.WKY-(D5Uwm78-D5Uwm84)/Uwm,female,160 days to 155 days,29,,CMO:0000343,mammary tumor number,,,,8.8,,0.7,3.7696,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70305,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003357,WF.WKY-(D5Uwm78-D5Uwm93)/Uwm,female,160 days to 155 days,27,,CMO:0000343,mammary tumor number,,,,5,,0.5,2.5981,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70306,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003356,WF.WKY-(D5Uwm78-D5Uwm84)/Uwm,female,160 days to 155 days,41,,CMO:0000343,mammary tumor number,,,,8.1,,0.6,3.8419,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70307,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003358,WF.WKY-(D5Uwm88-D5Uwm92)/Uwm,female,160 days to 155 days,58,,CMO:0000343,mammary tumor number,,,,6.9,,0.6,4.5695,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70308,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003359,WF.WKY-(D5Uwm87-D5Uwm92)/Uwm,female,160 days to 155 days,56,,CMO:0000343,mammary tumor number,,,,6.3,,0.4,2.9933,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70309,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003360,WF.WKY-(D5Uwm85-D5Uwm92)/Uwm,female,160 days to 155 days,51,,CMO:0000343,mammary tumor number,,,,3.9,,0.3,2.1424,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70310,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003361,WF.WKY-(D5Uwm82-D5Uwm92)/Uwm,female,160 days to 155 days,18,,CMO:0000343,mammary tumor number,,,,2.6,,0.6,2.5456,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70311,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003362,WF.WKY-(D5Uwm82-D5Uwm91)/Uwm,female,160 days to 155 days,58,,CMO:0000343,mammary tumor number,,,,3.4,,0.3,2.2847,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70312,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003363,WF.WKY-(D5Uwm77-D5Uwm91)/Uwm,female,160 days to 155 days,12,,CMO:0000343,mammary tumor number,,,,3.8,,0.8,2.7713,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70313,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0000984,WF/NHsd,female,160 days to 155 days,46,,CMO:0000343,mammary tumor number,,,,7.9,,0.5,3.3912,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70314,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0002605,WF.WKY-(D7Rat171-D7Rat128)/2Uwm,female,160 days to 155 days,32,,CMO:0000343,mammary tumor number,,,,3.9,,0.4596,2.6,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66061,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0002604,WF.WKY-(D7Rat171-D7Rat128)/1Uwm,female,160 days to 155 days,17,,CMO:0000343,mammary tumor number,,,,3.5,,0.6063,2.5,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66060,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0002606,WF.WKY-(D7Rat51-D7Rat128)/Uwm,female,160 days to 155 days,23,,CMO:0000343,mammary tumor number,,,,8,,0.8549,4.1,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66062,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0002607,WF.WKY-(D7Uwm25-D7Rat128)/Uwm,female,160 days to 155 days,43,,CMO:0000343,mammary tumor number,,,,7.2,,0.4575,3.0,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66063,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0002608,WF.WKY-(D7Rat171-D7Rat45)/Uwm,female,160 days to 155 days,28,,CMO:0000343,mammary tumor number,,,,3.4,,0.3969,2.1,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66064,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0002609,WF.COP-(D7Rat39-D7Uwm12)/1Uwm,female,160 days to 155 days,16,,CMO:0000343,mammary tumor number,,,,2.4,,0.4,1.6,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66065,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0002610,WF.COP-(D7Rat39-D7Uwm12)/2Uwm,female,160 days to 155 days,16,,CMO:0000343,mammary tumor number,,,,2,,0.375,1.5,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66066,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0000982,WF,female,160 days to 155 days,19,,CMO:0000343,mammary tumor number,,,,7.3,,0.8259,3.6,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66067,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",, 689,"Shepel LA, et al., Genetics 1998 May;149(1):289-99",mammary gland integrity trait,,RS:0000982,WF,female,200 days to 181 days,53,,CMO:0000343,mammary tumor number,,,,3.62,,0.2679,1.95,MMO:0000344,necropsy,,0.0,from 126 to 140 days,DMBA oral gavage,126,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (between 126 and 140 days)",66100,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (between 126 and 140 days)",, 1558,"Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7.",mammary gland integrity trait,,RS:0000064,Crl:CD(SD),female,365 days to 0 days,32,,CMO:0000343,mammary tumor number,,,,2.84,,0.31,1.7536,MMO:0000158,manual palpation method,,0.0,,,,,"maternal milk (for 20 days) and vehicle control condition (for 15 days) then 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days)",76264,maternal milk (for 20 days),vehicle control condition (for 15 days),"7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days)" 1558,"Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7.",mammary gland integrity trait,,RS:0000064,Crl:CD(SD),female,365 days to 0 days,34,,CMO:0000343,mammary tumor number,,,,3.82,,0.43,2.5073,MMO:0000158,manual palpation method,,0.0,,,,,"maternal milk (for 20 days) and bisphenol A (25 ug/kg) (for 15 days) then 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days)",76265,maternal milk (for 20 days),bisphenol A (25 ug/kg) (for 15 days),"7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days)" 1558,"Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7.",mammary gland integrity trait,,RS:0000064,Crl:CD(SD),female,365 days to 0 days,24,,CMO:0000343,mammary tumor number,,,,5,,0.88,4.3111,MMO:0000158,manual palpation method,,0.0,,,,,"maternal milk (for 20 days) and bisphenol A (250 ug/kg) (for 15 days) then 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days)",76266,maternal milk (for 20 days),bisphenol A (250 ug/kg) (for 15 days),"7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days)"